Which has preferable valuation and earnings, DRUG or IMUX?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.08 N/A Immunic N/A N/A -$97.17M -$4.38 N/A

Is DRUG or IMUX more profitable?

Bright Minds Biosciences' return on equity of -12.46% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -12.46% -12.30% Immunic N/A -157.89% -107.88%

Does the media favor DRUG or IMUX?

In the previous week, Bright Minds Biosciences had 4 more articles in the media than Immunic. MarketBeat recorded 5 mentions for Bright Minds Biosciences and 1 mentions for Immunic. Immunic's average media sentiment score of 1.76 beat Bright Minds Biosciences' score of 0.77 indicating that Immunic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is IMUX or CTNM more profitable?

Contineum Therapeutics' return on equity of -24.73% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -157.89% -107.88% Contineum Therapeutics N/A -24.73% -23.51%

Does the media refer more to IMUX or CTNM?

In the previous week, Contineum Therapeutics had 5 more articles in the media than Immunic. MarketBeat recorded 6 mentions for Contineum Therapeutics and 1 mentions for Immunic. Immunic's average media sentiment score of 1.76 beat Contineum Therapeutics' score of -0.20 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Contineum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OVID or IMUX more profitable?

Ovid Therapeutics' return on equity of -23.64% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Ovid Therapeutics N/A -23.64% -20.52% Immunic N/A -157.89% -107.88%

Do analysts rate CGC or IMUX?

Immunic has a consensus target price of $35.43, indicating a potential upside of 345.08%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Immunic 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.00

Is CGC or IMUX more profitable?

Immunic has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Canopy Growth -65.33% -21.91% -14.34% Immunic N/A -157.89% -107.88%

Does the media favor CGC or IMUX?

In the previous week, Canopy Growth had 13 more articles in the media than Immunic. MarketBeat recorded 14 mentions for Canopy Growth and 1 mentions for Immunic. Immunic's average media sentiment score of 1.76 beat Canopy Growth's score of 0.87 indicating that Immunic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 9 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Immunic (IMUX) Competitors

$7.96 -0.68 (-7.87%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$7.93 -0.03 (-0.40%)

As of 10/2/2026 07:59 PM Eastern

Compare

IMUX vs. DRUG, ASMB, CTNM, OVID, and CGC

Should you buy Immunic stock or one of its competitors? Immunic's main competitors and comparable companies include Bright Minds Biosciences (DRUG), Assembly Biosciences (ASMB), Contineum Therapeutics (CTNM), Ovid Therapeutics (OVID), and Canopy Growth (CGC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Immunic compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

Bright Minds Biosciences' return on equity of -12.46% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-12.46%	-12.30%
Immunic	N/A	-157.89%	-107.88%

Bright Minds Biosciences has a beta of -5.22, indicating that its stock price is 622% less volatile than the broader market. Comparatively, Immunic has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

In the previous week, Bright Minds Biosciences had 4 more articles in the media than Immunic. MarketBeat recorded 5 mentions for Bright Minds Biosciences and 1 mentions for Immunic. Immunic's average media sentiment score of 1.76 beat Bright Minds Biosciences' score of 0.77 indicating that Immunic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 5.5% of Immunic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Bright Minds Biosciences presently has a consensus target price of $143.83, indicating a potential upside of 183.75%. Immunic has a consensus target price of $35.43, indicating a potential upside of 345.08%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A

Summary

Immunic beats Bright Minds Biosciences on 7 of the 13 factors compared between the two stocks.

How does Immunic compare to Assembly Biosciences?

Immunic (NASDAQ:IMUX) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Immunic has a net margin of 0.00% compared to Assembly Biosciences' net margin of -0.06%. Assembly Biosciences' return on equity of -0.02% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Assembly Biosciences	-0.06%	-0.02%	-0.02%

In the previous week, Immunic had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 1 mentions for Immunic and 0 mentions for Assembly Biosciences. Immunic's average media sentiment score of 1.76 beat Assembly Biosciences' score of 0.00 indicating that Immunic is being referred to more favorably in the media.

Company	Overall Sentiment
Immunic	Very Positive
Assembly Biosciences	Neutral

51.8% of Immunic shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 5.5% of Immunic shares are held by insiders. Comparatively, 3.5% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Immunic presently has a consensus price target of $35.43, indicating a potential upside of 345.08%. Assembly Biosciences has a consensus price target of $47.50, indicating a potential upside of 110.74%. Given Immunic's stronger consensus rating and higher probable upside, equities research analysts clearly believe Immunic is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Immunic has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Assembly Biosciences has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Assembly Biosciences	$72.30M	6.35	-$6.12M	$1.02	22.10

Summary

Immunic beats Assembly Biosciences on 10 of the 16 factors compared between the two stocks.

How does Immunic compare to Contineum Therapeutics?

Immunic (NASDAQ:IMUX) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

Contineum Therapeutics' return on equity of -24.73% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Contineum Therapeutics	N/A	-24.73%	-23.51%

Immunic currently has a consensus target price of $35.43, indicating a potential upside of 345.08%. Contineum Therapeutics has a consensus target price of $22.17, indicating a potential upside of 68.95%. Given Immunic's stronger consensus rating and higher possible upside, research analysts plainly believe Immunic is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Contineum Therapeutics had 5 more articles in the media than Immunic. MarketBeat recorded 6 mentions for Contineum Therapeutics and 1 mentions for Immunic. Immunic's average media sentiment score of 1.76 beat Contineum Therapeutics' score of -0.20 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Contineum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunic has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Contineum Therapeutics has higher revenue and earnings than Immunic. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Contineum Therapeutics	$50M	9.87	-$59.98M	-$1.73	N/A

51.8% of Immunic shares are held by institutional investors. 5.5% of Immunic shares are held by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Immunic beats Contineum Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Immunic compare to Ovid Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Ovid Therapeutics' return on equity of -23.64% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	N/A	-23.64%	-20.52%
Immunic	N/A	-157.89%	-107.88%

Ovid Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Immunic has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

In the previous week, Immunic had 1 more articles in the media than Ovid Therapeutics. MarketBeat recorded 1 mentions for Immunic and 0 mentions for Ovid Therapeutics. Immunic's average media sentiment score of 1.76 beat Ovid Therapeutics' score of 0.00 indicating that Immunic is being referred to more favorably in the news media.

Company	Overall Sentiment
Ovid Therapeutics	Neutral
Immunic	Very Positive

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by company insiders. Comparatively, 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ovid Therapeutics has higher revenue and earnings than Immunic. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	64.11	-$17.41M	-$0.31	N/A
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A

Ovid Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 152.10%. Immunic has a consensus target price of $35.43, suggesting a potential upside of 345.08%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Ovid Therapeutics beats Immunic on 8 of the 15 factors compared between the two stocks.

How does Immunic compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Immunic has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-65.33%	-21.91%	-14.34%
Immunic	N/A	-157.89%	-107.88%

3.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 0.4% of Canopy Growth shares are owned by company insiders. Comparatively, 5.5% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Canopy Growth had 13 more articles in the media than Immunic. MarketBeat recorded 14 mentions for Canopy Growth and 1 mentions for Immunic. Immunic's average media sentiment score of 1.76 beat Canopy Growth's score of 0.87 indicating that Immunic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	9 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Immunic has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$251.01M	1.57	-$190.29M	-$0.45	N/A
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A

Immunic has a consensus target price of $35.43, indicating a potential upside of 345.08%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Canopy Growth has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Immunic has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

Summary

Immunic beats Canopy Growth on 11 of the 16 factors compared between the two stocks.

Get Immunic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMUX vs. The Competition

Export

Metric	Immunic	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$108.61M	$12.21B	$7.15B	$13.28B
Dividend Yield	N/A	2.65%	2.54%	17.33%
P/E Ratio	-1.82	799.70	275.67	26.04
Price / Sales	N/A	938.84	656.66	111.05
Price / Cash	N/A	86.66	78.87	52.62
Price / Book	-14.47	10.46	10.93	6.31
Net Income	-$97.17M	$2.84B	$3.51B	$362.16M
7 Day Performance	-14.87%	-1.56%	-2.00%	-1.66%
1 Month Performance	-39.28%	-5.58%	-6.19%	-4.68%
1 Year Performance	-18.63%	-2.40%	8.03%	1.57%

Immunic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMUX Immunic	3.2595 of 5 stars	$7.96 -7.9%	$35.43 +345.1%	-18.6%	$108.61M	N/A	N/A	95	Positive News
DRUG Bright Minds Biosciences	2.6127 of 5 stars	$51.66 -0.3%	$143.83 +178.4%	-4.8%	$504.13M	N/A	N/A	25	News Coverage Analyst Downgrade
ASMB Assembly Biosciences	2.6027 of 5 stars	$23.61 -0.3%	$47.50 +101.2%	-3.3%	$481.93M	$72.30M	23.15	73
CTNM Contineum Therapeutics	2.1025 of 5 stars	$12.73 +1.4%	$21.00 +65.0%	+15.6%	$472.52M	$50M	N/A	51	Analyst Forecast
OVID Ovid Therapeutics	1.742 of 5 stars	$2.46 +2.5%	$6.00 +143.9%	+29.3%	$468.71M	$7.25M	N/A	23	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMUX) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunic (IMUX) Competitors

IMUX vs. DRUG, ASMB, CTNM, OVID, and CGC

How does Immunic compare to Bright Minds Biosciences?

Summary

How does Immunic compare to Assembly Biosciences?

Summary

How does Immunic compare to Contineum Therapeutics?

Summary

How does Immunic compare to Ovid Therapeutics?

Summary

How does Immunic compare to Canopy Growth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunic (IMUX) Competitors

IMUX vs. DRUG, ASMB, CTNM, OVID, and CGC

How does Immunic compare to Bright Minds Biosciences?

Is DRUG or IMUX more profitable?

Which has more risk and volatility, DRUG or IMUX?

Does the media favor DRUG or IMUX?

Do insiders and institutionals believe in DRUG or IMUX?

Do analysts rate DRUG or IMUX?

Which has preferable valuation and earnings, DRUG or IMUX?

Summary

How does Immunic compare to Assembly Biosciences?

Is IMUX or ASMB more profitable?

Does the media refer more to IMUX or ASMB?

Do institutionals & insiders believe in IMUX or ASMB?

Do analysts rate IMUX or ASMB?

Which has more volatility & risk, IMUX or ASMB?

Which has better earnings & valuation, IMUX or ASMB?

Summary

How does Immunic compare to Contineum Therapeutics?

Is IMUX or CTNM more profitable?

Do analysts rate IMUX or CTNM?

Does the media refer more to IMUX or CTNM?

Which has more risk and volatility, IMUX or CTNM?

Which has higher valuation & earnings, IMUX or CTNM?

Do institutionals and insiders believe in IMUX or CTNM?

Summary

How does Immunic compare to Ovid Therapeutics?

Is OVID or IMUX more profitable?

Which has more risk & volatility, OVID or IMUX?

Does the media favor OVID or IMUX?

Do insiders & institutionals have more ownership in OVID or IMUX?

Which has higher earnings & valuation, OVID or IMUX?

Do analysts rate OVID or IMUX?

Summary

How does Immunic compare to Canopy Growth?

Is CGC or IMUX more profitable?

Do institutionals and insiders believe in CGC or IMUX?

Does the media favor CGC or IMUX?

Which has preferable valuation and earnings, CGC or IMUX?

Do analysts rate CGC or IMUX?

Which has more volatility & risk, CGC or IMUX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools